State of Wyoming Has $353,000 Stock Holdings in Johnson & Johnson $JNJ

Key Points

• The State of Wyoming reduced its stake in Johnson & Johnson by 79.3%, selling 8,153 shares, leaving it with 2,131 shares valued at $353,000.
• Analysts' ratings for Johnson & Johnson exhibit mixed sentiments, with Citigroup raising its target price to $200 and maintaining a "buy" rating, while Leerink Partners downgraded from "outperform" to "market perform" with a reduced target of $153.
• Johnson & Johnson recently announced a quarterly dividend of $1.30, reflecting an annualized dividend of $5.20 and a yield of 2.9%.

State of Wyoming decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 79.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,131 shares of the company's stock after selling 8,153 shares during the quarter. State of Wyoming's holdings in Johnson & Johnson were worth $353,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Trexquant Investment LP purchased a new stake in shares of Johnson & Johnson in the first quarter valued at about $15,964,000. Gerber Kawasaki Wealth & Investment Management lifted its holdings in shares of Johnson & Johnson by 9.1% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,364 shares of the company's stock valued at $558,000 after purchasing an additional 282 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $497,000. Northstar Financial Companies Inc. raised its position in shares of Johnson & Johnson by 11.4% in the first quarter. Northstar Financial Companies Inc. now owns 11,437 shares of the company's stock valued at $1,897,000 after buying an additional 1,174 shares during the last quarter. Finally, Oak Associates Ltd. OH raised its position in shares of Johnson & Johnson by 2.9% in the first quarter. Oak Associates Ltd. OH now owns 10,483 shares of the company's stock valued at $1,739,000 after buying an additional 300 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.35 on Wednesday, reaching $177.71. 6,832,001 shares of the company's stock were exchanged, compared to its average volume of 8,970,639. The firm has a market capitalization of $427.98 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The business's 50-day moving average is $167.02 and its two-hundred day moving average is $160.33. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Bank of America boosted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.